Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

One-Year Outcome and Its Prediction in First-Episode Schizophrenia – A Naturalistic Study

Bachmann S.a · Bottmer C.b · Schröder J.b

Author affiliations

aDepartment of Psychiatry and Psychotherapy, University of Halle, Halle, and bSection of Geriatric Psychiatry, Department of Psychiatry, University of Heidelberg, Heidelberg, Germany

Related Articles for ""

Psychopathology 2008;41:115–123

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: February 23, 2006
Accepted: March 16, 2007
Published online: December 05, 2007
Issue release date: December 2007

Number of Print Pages: 9
Number of Figures: 1
Number of Tables: 1

ISSN: 0254-4962 (Print)
eISSN: 1423-033X (Online)

For additional information: https://www.karger.com/PSP

Abstract

Background: The literature suggests that the early course of schizophrenia is a strong predictor of long-term outcome. We sought to test this notion in a sample of first-episode patients. Sampling and Methods: Forty patients with a first episode of DSM-IV diagnoses of schizophrenia, schizoaffective, or schizophreniform disorder were assessed with well-established instruments such as the Positive and Negative Syndrome Scale and the Strauss-Carpenter Scale. Reassessment was performed 14 months later and included the Global Assessment of Functioning Scale in addition to the aforementioned instruments and a psychiatric interview. Regression analyses for the Global Assessment of Functioning Scale and symptomatology were used to identify outcome predictors. Results: At follow-up, 27 patients (67.5%) were in remission. Women’s outcome was significantly better with respect to intimate relationships and domiciliary independence. Although symptomatology of the whole group remained stable during the follow-up period, a subgroup of patients experienced a significant decrease in symptom levels whereas symptoms increased in another subgroup. The most important predictor of outcome was compliance with atypical antipsychotic medication during the follow-up period. Conclusions: These results suggest that there is a prognostic divide early in the course of the disease, that compliance with medication is of overriding importance towards 1-year outcome, and that for the individual patient the question of chronicity may be answered very early in the course of the disease.

© 2007 S. Karger AG, Basel


References

  1. Bleuler M: Die schizophrenen Geistesstörungen im Lichte langjähriger Kranken- und Familiengeschichten. Stuttgart, Thieme, 1972, p 513.
  2. Huber G, Gross G, Schuettler R: Schizophrenia. Clinical course and social psychiatric long-term examinations of schizophrenic patients hospitalized in Bonn from 1945 to 1959. Monogr Gesamtgeb Psychiatr Psychiatry Ser 1979;21:1–399.
  3. Ciompi L, Medvecka J: Comparative study of long-term mortality in the mentally ill. Schweiz Arch Neurol Neurochir Psychiatr 1976;118:111–135.
  4. Harding CM: Course types in schizophrenia: an analysis of European and American studies. Schizophr Bull 1988;14:633–643.
  5. Harding CM, Brooks GW, Ashikaga T, Strauss JS, Breier A: The Vermont longitudinal study of persons with severe mental illness. I. Methodology, study sample, and overall status 32 years later. Am J Psychiatry 1987;144:718–726.
  6. Marneros A, Deister A, Rohde A: Psychopathological and social status of patients with affective, schizophrenic and schizoaffective disorders after long-term course. Acta Psychiatr Scand 1990;82:352–358.
  7. Marneros A, Steinmeyer EM, Deister A, Rohde A, Junemann H: Long-term outcome of schizoaffective and schizophrenic disorders: a comparative study. III. Social consequences. Eur Arch Psychiatry Neurol Sci 1989;238:135–139.
  8. Helgason L: Twenty years’ follow-up of first psychiatric presentation for schizophrenia: what could have been prevented? Acta Psychiatr Scand 1990;81:231–235.
  9. Breier A, Schreiber JL, Dyer J, Pickar D: National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry 1991;48:239–246.
  10. Carone BJ, Harrow M, Westermeyer JF: Posthospital course and outcome in schizophrenia. Arch Gen Psychiatry 1991;48:247–253.
  11. Carpenter WT Jr, Strauss JS: The prediction of outcome in schizophrenia. 4. Eleven-year follow-up of the Washington IPSS cohort. J Nerv Ment Dis 1991;179:517–525.
  12. Johnstone EC, Frith CD, Crow TJ, Owens DG, Done DJ, Baldwin EJ, Charlette A: The Northwick Park ‘Functional’ Psychosis Study: diagnosis and outcome. Psychol Med 1992;22:331–346.
  13. Geddes J, Mercer G, Frith CD, MacMillan F, Owens DG, Johnstone EC: Prediction of outcome following a first episode of schizophrenia. A follow-up study of Northwick Park first episode study subjects. Br J Psychiatry 1994;165:664–668.
  14. Harrison G, Mason P, Glazebrook C, Medley I, Croudace T, Docherty S: Residence of incident cohort of psychotic patients after 13 years of follow-up. BMJ 1994;308:813–816.
  15. DeSisto M, Harding CM, McCormick RV, Ashikaga T, Brooks GW: The Maine and Vermont three-decade studies of serious mental illness. II. Longitudinal course comparisons. Br J Psychiatry 1995;167:338–342.
  16. Mason P, Harrison G, Glazebrook C, Medley I, Dalkin T, Croudace T: Characteristics of outcome in schizophrenia at 13 years. Br J Psychiatry 1995;167:596–603.
  17. Sartorius N, Gulbinat W, Harrison G, Laska E, Siegel C: Long-term follow-up of schizophrenia in 16 countries. A description of the International Study of Schizophrenia conducted by the World Health Organization. Soc Psychiatry Psychiatr Epidemiol 1996;31:249–258.
  18. Sartorius N, Jablensky A, Korten A, Ernberg G, Anker M, Cooper JE, Day R: Early manifestations and first-contact incidence of schizophrenia in different cultures. A preliminary report on the initial evaluation phase of the WHO Collaborative Study on determinants of outcome of severe mental disorders. Psychol Med 1986;16:909–928.
  19. Leon CA: Clinical course and outcome of schizophrenia in Cali, Colombia. A 10-year follow-up study. J Nerv Ment Dis 1989;177:593–606.
  20. Davidson L, McGlashan TH: The varied outcomes of schizophrenia. Can J Psychiatry 1997;42:34–43.
  21. Larsen TK, McGlashan TH, Johannessen JO, Friis S, Guldberg C, Haahr U, Horneland M, Melle I, Moe LC, Opjordsmoen S, Simonsen E, Vaglum P: Shortened duration of untreated first episode of psychosis: changes in patient characteristics at treatment. Am J Psychiatry 2001;158:1917–1919.
  22. Melle I, Larsen TK, Haahr U, Friis S, Johannessen JO, Opjordsmoen S, Simonsen E, Rund BR, Vaglum P, McGlashan T: Reducing the duration of untreated first-episode psychosis: effects on clinical presentation. Arch Gen Psychiatry 2004;61:143–150.
  23. Angst J: European long-term follow-up studies of schizophrenia. Schizophr Bull 1988;14:501–513.
  24. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G: One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994;151:1409–1416.
  25. Sartorius N, Jablensky A, Shapiro R: Two-year follow-up of the patients included in the WHO International Pilot Study of Schizophrenia. Psychol Med 1977;7:529–541.
  26. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen A: Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl 1992;20:1–97.
  27. Haefner H, an der Heiden W: Course and outcome of schizophrenia; in Hirsch SR, Weinberger DR (eds): Schizophrenia, ed 2. Oxford, Blackwell Science, 2003, pp 101–141.
  28. Harrison G, Hopper K, Craig T, Laska E, Siegel C, Wanderling J, Dube KC, Ganev K, Giel R, an der Heiden W, et al: Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry 2001;178:506–517.
  29. Harrison G, Amin S, Singh SP, Croudace T, Jones P: Outcome of psychosis in people of African-Caribbean family origin. Population-based first-episode study. Br J Psychiatry 1999;175:43–49.
  30. Leff JP, Hirsch SR, Gaind R, Rhode PD, Stevens BC: Life events and maintenance therapy in schizophrenic relapse. Br J Psychiatry 1973;123:659–660.
  31. Gift TE, Strauss JS, Harder DW, Kokes RF, Ritzler BA: Established chronicity of psychotic symptoms in first-admission schizophrenic patients. Am J Psychiatry 1981;138:779–784.
  32. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR: Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992;149:1183–1188.
  33. Harrison G, Croudace T, Mason P, Glazebrook C, Medley I: Predicting the long-term outcome of schizophrenia. Psychol Med 1996;26:697–705.
  34. Lieberman JA, Koreen AR, Chakos M, Sheitman B, Woerner M, Alvir JM, Bilder R: Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996;57(suppl 9):5–9.
    External Resources
  35. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC: A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986;148:120–127.
  36. May P, Tuma AH: Treatment of schizophrenia: an experimental study of five treatment methods. Br J Psychiatry 1965;111:503–510.
    External Resources
  37. Waddington J: The clinical psychopharmacology of antipsychotic drugs in schizophrenia; in Hirsch SR, Weinberger DR (eds): Schizophrenia. Oxford, Blackwell, 1995, pp 341–357.
  38. Meltzer HY: Outcome in schizophrenia: beyond symptom reduction. J Clin Psychiatry 1999;60(suppl 3):3–8.
    External Resources
  39. Wittchen HU, Wunderlich U, Gruschwitz S, Zaudig M: SKID-I. Strukturiertes klinisches Interview für DSM-IV. Göttingen, Hogrefe, 1997.
  40. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–276.
  41. Strauss JS, Carpenter WT Jr: The prediction of outcome in schizophrenia. II. Relationships between predictor and outcome variables: a report from the WHO international pilot study of schizophrenia. Arch Gen Psychiatry 1974;31:37–42.
  42. Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11–19.
  43. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672–676.
  44. National Institute of Mental Health: Abnormal Involuntary Movement Scale (AIMS); in Guy WE (ed): Early Clinical Drug Evaluation Unit Assessment. Rockville, Department of Health and Human Services, 1976, pp 266–268.
  45. American Psychiatric Association: Diagnostic and Statistic Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
  46. Eaton WW, Mortensen PB, Herrman H, Freeman H, Bilker W, Burgess P, Wooff K: Long-term course of hospitalization for schizophrenia. I. Risk for rehospitalization. Schizophr Bull 1992;18:217–228.
  47. McGlashan TH: Early detection and intervention of schizophrenia: rationale and research. Br J Psychiatry Suppl 1998;172:3–6.
  48. Gupta S, Andreasen NC, Arndt S, Flaum M, Hubbard WC, Ziebell S: The Iowa Longitudinal Study of Recent Onset Psychosis: one-year follow-up of first episode patients. Schizophr Res 1997;23:1–13.
  49. Black K, Peters L, Rui Q, Milliken H, Whitehorn D, Kopala LC: Duration of untreated psychosis predicts treatment outcome in an early psychosis program. Schizophr Res 2001;47:215–222.
  50. Malla AK, Norman RM, Takhar J, Manchanda R, Townsend L, Scholten D, Haricharan R: Can patients at risk for persistent negative symptoms be identified during their first episode of psychosis? J Nerv Ment Dis 2004;192:455–463.
    External Resources
  51. Bachmann S, Bottmer C, Schroeder J: Neurological soft signs in first-episode schizophrenia – A follow-up study. Am J Psychiatry 2005;162:1–7.
    External Resources
  52. Johnstone EC, Frith CD, Gold A, Stevens M: The outcome of severe acute schizophrenic illnesses after one year. Br J Psychiatry 1979;134:28–33.
  53. McCreadie RG, Wiles D, Grant S, Crockett GT, Mahmood Z, Livingston MG, Watt JA, Greene JG, Kershaw PW, Todd NA, et al: The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group. Acta Psychiatr Scand 1989;80:597–602.
  54. Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, Woerner M, Borenstein M: Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993;50:369–376.
  55. Rabiner CJ, Wegner JT, Kane JM: Outcome study of first-episode psychosis. I. Relapse rates after 1 year. Am J Psychiatry 1986;143:1155–1158.
  56. Craig TJ, Bromet EJ, Fennig S, Tanenberg-Karant M, Lavelle J, Galambos N: Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series? Am J Psychiatry 2000;157:60–66.
  57. Larsen TK, Moe LC, Vibe-Hansen L, Johannessen JO: Premorbid functioning versus duration of untreated psychosis in 1 year outcome in first-episode psychosis. Schizophr Res 2000;45:1–9.
  58. Shepherd M, Watt D, Falloon I, Smeeton N: The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psychol Med Suppl 1989;15:1–46.
  59. Leary J, Johnstone EC, Owens DG: Social outcome. Br J Psychiatry Suppl 1991;13:13–20, 44–46.
  60. May PR, Tuma AH, Dixon WJ, Yale C, Thiele DA, Kraude WH: Schizophrenia. A follow-up study of the results of five forms of treatment. Arch Gen Psychiatry 1981;38:776–784.
  61. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Lieberman JA: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241–247.
  62. Ram R, Bromet EJ, Eaton WW, Pato C, Schwartz JE: The natural course of schizophrenia: a review of first-admission studies. Schizophr Bull 1992;18:185–207.
  63. Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Bilder R, Goldman R, Lieberman JA: Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156:544–549.
  64. Keshavan MS, Schooler NR: First-episode studies in schizophrenia: criteria and characterization. Schizophr Bull 1992;18:491–513.
  65. Mathalon DH, Sullivan EV, Lim KO, Pfefferbaum A: Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry 2001;58:148–157.
  66. Coryell W, Tsuang MT: DSM-III schizophreniform disorder. Comparisons with schizophrenia and affective disorder. Arch Gen Psychiatry 1982;39:66–69.
  67. Fenton WS: Course and outcome in schizophrenia. Curr Opin Psychiatry 1997;10:40–44.
    External Resources
  68. Fenton WS, McGlashan TH: Sustained remission in drug-free schizophrenic patients. Am J Psychiatry 1987;144:1306–1309.
  69. Johnstone EC, Macmillan JF, Frith CD, Benn DK, Crow TJ: Further investigation of the predictors of outcome following first schizophrenic episodes. Br J Psychiatry 1990;157:182–189.
  70. Haas GL, Sweeney JA: Premorbid and onset features of first-episode schizophrenia. Schizophr Bull 1992;18:373–386.
  71. Beiser M, Erickson D, Fleming JA, Iacono WG: Establishing the onset of psychotic illness. Am J Psychiatry 1993;150:1349–1354.
  72. Haas GL, Garratt LS, Sweeney JA: Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness. J Psychiatr Res 1998;32:151–159.
  73. Robinson DG, Woerner MG, McMeniman M, Mendelowitz A, Bilder RM: Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161:473–479.
  74. Johnstone EC, Crow TJ, Johnson AL, MacMillan JF: The Northwick Park Study of first episodes of schizophrenia. 1. Presentation of the illness and problems relating to admission. Br J Psychiatry 1986;148:115–120.
  75. McGlashan TH: The prediction of outcome in chronic schizophrenia. 4. The Chestnut Lodge follow-up study. Arch Gen Psychiatry 1986;43:167–176.
  76. Vazquez-Barquero J, Cuesta Nunez MJ, Herrera Castanedo S, Diez Manrique JF, Pardo G, Dunn G: Sociodemographic and clinical variables as predictors of the diagnostic characteristics of first episodes of schizophrenia. Acta Psychiatr Scand 1996;94:149–155.
  77. Angermeyer MC, Kuehn L: Gender differences in age at onset of schizophrenia. An overview. Eur Arch Psychiatry Neurol Sci 1988;237:351–364.
  78. Bleuler E: Lehrbuch der Psychiatrie. Berlin, Springer, 1979.
  79. Zarate CJ, Tohen M, Land M: First-episode schizophreniform disorder: comparisons with first-episode schizophrenia. Schizophr Res 2000;46:31–34.
    External Resources
  80. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR: Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005;162:441–449.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: February 23, 2006
Accepted: March 16, 2007
Published online: December 05, 2007
Issue release date: December 2007

Number of Print Pages: 9
Number of Figures: 1
Number of Tables: 1

ISSN: 0254-4962 (Print)
eISSN: 1423-033X (Online)

For additional information: https://www.karger.com/PSP


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.